A Randomised, Placebo-controlled, Double-blind, Parallel Groups, Multinational, Multicentre Trial Assessing the Effect of Barusiban Administered Subcutaneously on the Day of Transfer on Implantation and Pregnancy Rates in IVF/ICSI Patients
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Barusiban (Primary)
- Indications Female infertility
- Focus Therapeutic Use
- Acronyms BASIC
- Sponsors Ferring Pharmaceuticals
- 14 Oct 2019 According to a Ferring Pharmaceuticals media release, data from this trial will be presented at the 2019 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo taking place on October 12-16, 2019, in Philadelphia, Pennsylvania.
- 31 Aug 2018 Biomarkers information updated
- 15 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record..